Kristian B. Filion, PhD; Oriana H. Yu, MD, MSc
Acknowledgment: The authors thank Dr. Laurent Azoulay for his helpful suggestions on an earlier version of this editorial.
Financial Support: Dr. Filion holds a Chercheur-Boursier Junior II award from the Fonds de Recherche du Québec – Santé (Quebec Foundation for Health Research) and a William Dawson Scholar award from McGill University. Dr. Yu holds a Chercheur-Boursier Clinicien Junior 1 award from the Fonds de Recherche du Québec – Santé.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-1950.
Corresponding Author: Kristian B. Filion, PhD, Associate Professor and William Dawson Scholar, Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Centre for Clinical Epidemiology, Lady Davis Institute - Jewish General Hospital, 3755 Cote Ste-Catherine Road, H-410.1, Montreal, Quebec H3T 1E2, Canada; e-mail, email@example.com.
Current Author Addresses: Dr. Filion: Lady Davis Institute - Jewish General Hospital, 3755 Cote Ste-Catherine Road, H-410.1, Montreal, Quebec H3T 1E2, Canada.
Dr. Yu: Lady Davis Institute - Jewish General Hospital, 3755 Cote Ste-Catherine Road, E-104, Montreal, Quebec H3T 1E2, Canada.
Filion KB, Yu OH. Sodium–Glucose Cotransporter-2 Inhibitors and Severe Urinary Tract Infections: Reassuring Real-World Evidence. Ann Intern Med. 2019;171:289–290. [Epub ahead of print 30 July 2019]. doi: https://doi.org/10.7326/M19-1950
Download citation file:
Published: Ann Intern Med. 2019;171(4):289-290.
Published at www.annals.org on 30 July 2019
Infectious Disease, Nephrology, Urinary Tract Infection, Urological Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use